Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder
BackgroundUrothelial carcinoma of the bladder (UCB) is a common cancer of the urinary system. Despite substantial improvements in available treatment options, the survival outcome of patients with advanced UCB is unsatisfactory. Therefore, it is necessary to identify new prognostic biomarkers for mo...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.771036/full |
| _version_ | 1798032046437695488 |
|---|---|
| author | Yu Li Keying Zhang Fa Yang Dian Jiao Mingyang Li Xiaolong Zhao Chao Xu Shaojie Liu Hongji Li Shengjia Shi Bo Yang Lijun Yang Donghui Han Weihong Wen Weijun Qin |
| author_facet | Yu Li Keying Zhang Fa Yang Dian Jiao Mingyang Li Xiaolong Zhao Chao Xu Shaojie Liu Hongji Li Shengjia Shi Bo Yang Lijun Yang Donghui Han Weihong Wen Weijun Qin |
| author_sort | Yu Li |
| collection | DOAJ |
| description | BackgroundUrothelial carcinoma of the bladder (UCB) is a common cancer of the urinary system. Despite substantial improvements in available treatment options, the survival outcome of patients with advanced UCB is unsatisfactory. Therefore, it is necessary to identify new prognostic biomarkers for monitoring and therapy guidance of UCB. In recent years, prostate-specific membrane antigen (PSMA) and CD248 have been identified promising candidate bio7markers.MethodsIn this study, we first examined PSMA and CD248 expression in tissues from 124 patients with UCB using immunohistochemical and immunofluorescent staining. We then analyzed the association between the expression of the two biomarkers and other clinicopathological features and prognosis. Finally, we performed bioinformatic analysis of CD248 and FOLH 1 (PSMA) using the TCGA-BLCA dataset to explore the underlying mechanism of PSMA and CD248 in the progression of UCB.ResultsAmong the 124 cases, PSMA and CD248 were confirmed to be expressed in tumor-associated vessels. Vascular PSMA and CD248 expression levels were associated significantly with several deteriorated clinicopathological features. Furthermore, using univariate and multivariate Cox analyses, high vascular PSMA and CD248 expression levels were observed to be associated significantly with poor prognosis in patients with UCB. As risk factors, both PSMA and CD248 expression showed good performance to predict prognosis. Furthermore, combining these vascular molecules with other clinical risk factors generated a risk score that could promote predictive performance. Bioinformatic analysis showed that both PSMA and CD248 might contribute to angiogenesis and promote further progression of UCB.ConclusionBoth PSMA and CD248 are specifically expressed in the tumor-associated vasculature of UCB. These two molecules might be used as novel prognostic biomarkers and vascular therapeutic targets for UCB. |
| first_indexed | 2024-04-11T20:06:33Z |
| format | Article |
| id | doaj.art-fc57cfb44040442b8f50e32af516e52f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T20:06:33Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-fc57cfb44040442b8f50e32af516e52f2022-12-22T04:05:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-11-011110.3389/fonc.2021.771036771036Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the BladderYu Li0Keying Zhang1Fa Yang2Dian Jiao3Mingyang Li4Xiaolong Zhao5Chao Xu6Shaojie Liu7Hongji Li8Shengjia Shi9Bo Yang10Lijun Yang11Donghui Han12Weihong Wen13Weijun Qin14Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Pathology, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaAssisted Reproduction Center, Northwest Women’s and Children’s Hospital, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaInstitute of Medical Research, Northwestern Polytechnical University, Xi’an, ChinaDepartment of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaBackgroundUrothelial carcinoma of the bladder (UCB) is a common cancer of the urinary system. Despite substantial improvements in available treatment options, the survival outcome of patients with advanced UCB is unsatisfactory. Therefore, it is necessary to identify new prognostic biomarkers for monitoring and therapy guidance of UCB. In recent years, prostate-specific membrane antigen (PSMA) and CD248 have been identified promising candidate bio7markers.MethodsIn this study, we first examined PSMA and CD248 expression in tissues from 124 patients with UCB using immunohistochemical and immunofluorescent staining. We then analyzed the association between the expression of the two biomarkers and other clinicopathological features and prognosis. Finally, we performed bioinformatic analysis of CD248 and FOLH 1 (PSMA) using the TCGA-BLCA dataset to explore the underlying mechanism of PSMA and CD248 in the progression of UCB.ResultsAmong the 124 cases, PSMA and CD248 were confirmed to be expressed in tumor-associated vessels. Vascular PSMA and CD248 expression levels were associated significantly with several deteriorated clinicopathological features. Furthermore, using univariate and multivariate Cox analyses, high vascular PSMA and CD248 expression levels were observed to be associated significantly with poor prognosis in patients with UCB. As risk factors, both PSMA and CD248 expression showed good performance to predict prognosis. Furthermore, combining these vascular molecules with other clinical risk factors generated a risk score that could promote predictive performance. Bioinformatic analysis showed that both PSMA and CD248 might contribute to angiogenesis and promote further progression of UCB.ConclusionBoth PSMA and CD248 are specifically expressed in the tumor-associated vasculature of UCB. These two molecules might be used as novel prognostic biomarkers and vascular therapeutic targets for UCB.https://www.frontiersin.org/articles/10.3389/fonc.2021.771036/fullPSMACD248urothelial carcinoma of the bladderprognosisangiogenesis |
| spellingShingle | Yu Li Keying Zhang Fa Yang Dian Jiao Mingyang Li Xiaolong Zhao Chao Xu Shaojie Liu Hongji Li Shengjia Shi Bo Yang Lijun Yang Donghui Han Weihong Wen Weijun Qin Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder Frontiers in Oncology PSMA CD248 urothelial carcinoma of the bladder prognosis angiogenesis |
| title | Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder |
| title_full | Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder |
| title_fullStr | Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder |
| title_full_unstemmed | Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder |
| title_short | Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder |
| title_sort | prognostic value of vascular expressed psma and cd248 in urothelial carcinoma of the bladder |
| topic | PSMA CD248 urothelial carcinoma of the bladder prognosis angiogenesis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.771036/full |
| work_keys_str_mv | AT yuli prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT keyingzhang prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT fayang prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT dianjiao prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT mingyangli prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT xiaolongzhao prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT chaoxu prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT shaojieliu prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT hongjili prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT shengjiashi prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT boyang prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT lijunyang prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT donghuihan prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT weihongwen prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder AT weijunqin prognosticvalueofvascularexpressedpsmaandcd248inurothelialcarcinomaofthebladder |